Freeline to Present New Clinical Data for FLT201 in Gaucher Disease in Oral Presentation at Upcoming ESGCT 30th Annual Congress
October 16, 2023 07:00 ET
|
Freeline Therapeutics Holdings plc
Freeline to Present New Clinical Data for FLT201 in Gaucher Disease in Oral Presentation at Upcoming ESGCT 30 th Annual Congress
Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease
October 04, 2023 07:00 ET
|
Freeline Therapeutics Holdings plc
Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher
Freeline Reports Second Quarter 2023 Financial Results and Business Highlights
August 15, 2023 07:00 ET
|
Freeline Therapeutics Holdings plc
Completed dosing in first cohort of Phase 1/2 GALILEO-1 trial of FLT201 in Gaucher disease; expect to report initial clinical data in third quarter of 2023 Extending impact of its novel GCase...
Freeline Therapeutics to Host Second Quarter 2023 Financial Results Call
August 08, 2023 07:30 ET
|
Freeline Therapeutics Holdings plc
LONDON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August...
Freeline to Participate in Upcoming Investor Conferences
July 31, 2023 07:30 ET
|
Freeline Therapeutics Holdings plc
LONDON, July 31, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the company will be participating in two upcoming investor conferences in August....
Freeline to Host Virtual KOL Event on its Gene Therapy Candidate, FLT201, in Gaucher Disease
July 25, 2023 07:30 ET
|
Freeline Therapeutics Holdings plc
LONDON, July 25, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced it will host a virtual Key Opinion Leader (KOL) event on FLT201, its adeno-associated...
Freeline Announces First Patient Dosed with Its Novel Gene Therapy Candidate for Gaucher Disease and Unveils Research Program in GBA1-linked Parkinson’s Disease
June 26, 2023 07:30 ET
|
Freeline Therapeutics Holdings plc
FLT201 is a highly differentiated AAV gene therapy candidate that delivers a longer-acting engineered variant of GCase, the enzyme missing in people with Gaucher disease Company expects to report...
Freeline to Present at 2023 Jefferies Healthcare Conference
June 02, 2023 08:00 ET
|
Freeline Therapeutics Holdings plc
LONDON, June 02, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that its Chief Executive Officer Michael Parini will present at the 2023 Jefferies...
Freeline Reports First Quarter 2023 Financial Results and Business Highlights
May 30, 2023 07:30 ET
|
Freeline Therapeutics Holdings plc
Expect to report initial clinical data for FLT201 in Gaucher disease in third quarter of 2023 FLT201 granted ILAP designation, which aims to accelerate time to market and facilitate patient access in...
Freeline Granted ILAP Designation in United Kingdom by MHRA for FLT201, an Investigational Gene Therapy for the Treatment of Gaucher Disease
May 22, 2023 08:00 ET
|
Freeline Therapeutics Holdings plc
LONDON, May 22, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that FLT201 has been awarded the Innovation Passport for the treatment of Gaucher disease...